Skip to main content
. Author manuscript; available in PMC: 2009 May 4.
Published in final edited form as: Bioorg Med Chem. 2007 Oct 18;16(2):762–770. doi: 10.1016/j.bmc.2007.10.040

Table 1.

Binding affinity and potency of CO23 analogues

Kd and EC50 values (nM)
Binding affinity (Kd)a
Transactivation in U2OS cells (EC50)b
Transactivation in HeLa cells (EC50)b
Compound TRα TRβ TRα TRβ TRα TRβ
T3c 0.058 0.081 2.4 ± 0.4 11 ± 2 2.4 ± 0.5 2.4 ± 0.5
CO23c 1.2 ± 0.2 1.7± 0.3 34 ± 4 390 ± 3 11 ± 1 58 ± 1
CO24 17 ± 1 18.4 ± 1 128 ± 5 421 ± 3 8.4 ± 3 32 ± 3
CO26 82 ± 21 119 ± 30 870 ± 160 8000 ± 1800 42 ± 6 265 ± 10
CO27 42 ± 13 53 ± 17 146 ± 28 4000 ± 1000 27 ± 6 180 ± 30
CO28 15 ± 6 18 ± 2 87 ± 14 1400 ± 170 10 ± 1 27 ± 6
CO29 25 ± 7 49 ± 5 145 ± 10 2000 ± 290 39 ± 4 100 ± 14
CO30 1700 ± 10 2000 ± 360 >20000d >20000d >10000d >10000d
CO31 24 ± 3 36 ± 1 105 ± 8 2000 ± 170 21 ± 3 216 ± 80
CO32 43 ± 6 68 ± 10 206 ± 41 5200 ± 670 44 ± 1 530 ± 170
a

Determined by means of an 125I-T3 competitive binding assay and data is reported as the mean Kd ± standard error of the mean, n=3.

b

Determined through use of a TRE-driven dual-luciferase reporter assay in U2OS or HeLa cells and the data is reported as the mean EC50 value ± standard error of the mean, n=3.

c

See reference 36.

d

Dose-response curves generated using CO30 in transactivation assays did not plateau, and hence the EC50 value is an approximated value based on extrapolation.